login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

The impact of the STOP-VT study


Monday, 24 Oct 2011 16:43
Rainer Moosdorf
Rainer Moosdorf


The STOP VT study, as reported in the 14th issue of Cardiac Rhythm News, showed that remote magnetic navigation may provide additional benefits to catheter ablation for the treatment of scar-related ventricular tachycardia. Rainer Moosdorf, Department of Cardiovascular Surgery, Philipps – University Marburg Medical School, Germany, reviews the impact of this study.


 

By Rainer Moosdorf 



The STOP VT study is remarkable in two aspects. The first one is that, with the new magnetic steering technology, ablation of scar related ventricular tachycardia has become more reliable and more successful and the investigators of the study have to be congratulated for their good results. These results should—and this is the second aspect—remind us, that ventricular tachycardia do nearly always have a pathological substrate at the border between scar and vital myocardium, which may be addressed by different ablation techniques as a curative therapy in contrast to the implantable cardioverter device (ICD), which is highly effective in terminating ventricular arrhythmias but is not treating the disease.

 

There are numerous patients with VTs who will benefit from curative attempts not only in terms of cardiac mortality but also in terms of quality of life. This makes a significant difference to the ICD. The new ablation technologies described will widen the field of interventional options and surgical options, and should be considered in any patients with documented VTs and an indication for cardiac surgery.

 

A working group at University Marburg Medical School, including myself, and Robert Svenson, cardiologist and electrophysiologists, Carolinas Heart Center in Charlotte, North Carolina, before retiring, have developed a mapping guided laser ablation technique, which may be applied endo- and epicardially without significantly increasing the procedural time or increasing  the risk of complications during cardiac operations. Importantly we have learned from clinical studies that besides the well known subendocardial re-entry circuits, there are also subepicardial circuits that should be mapped and ablated to avoid recurrences. This is still a weak point of all catheter based techniques, which are limited to a sole endocardial ablation.

 

The endo- and epicardial approach is applied in the presence of major scar or aneurysms and has a cure rate of more than 90% (freedom from any inducible VT) (Moosdorf R, et al. American Heart Journal 1994; 127: 1133–38) and even the sole epicardial ablation, which may avoid a ventriculostomy in the absence of major scar, has a cure rate of around 60% (D Pfeiffer, et al. Circulation 1996; 94:3221–25). This means that with the combined approach, the vast majority of patients may be left without an ICD and will not experience any shocks.

 

Even the limited epicardial ablation provides a success rate of more than half. Additionally, many of the remaining patients, who received an ICD, did not experience a clinical ventricular tachycardia with the necessity of a shock. It may be expected that curative techniques, may they be interventional or surgical, will attract more interest again in the treatment of patients with ventricular tachycardia.

 

 

 

 




Add New Comment

Related Items


Most popular


Medical devices available in the EU before the USA are at higher risk for emergence of safety issues
Thursday, 30 Jun 2016
A cohort study has found that medical devices approved first in the European Union (EU) are associated with a greater rate of post-marketing safety alerts and recalls compared with devices approved ... Medical devices available in the EU before the USA are at higher risk for emergence of safety issues

CorMatrix CanGaroo ECM envelope receives CE mark approval
Wednesday, 29 Jun 2016
CorMatrix Cardiovascular has received CE mark approval for its CorMatrix CanGaroo ECM envelope. The company received US Food and Drug Administration clearance to market the device in August 2014. CorMatrix CanGaroo ECM envelope receives CE mark approval

Ablation of frequent premature ventricular complex allows safe withholding of ICD implant
Thursday, 30 Jun 2016
Patients with frequent premature ventricular complex and primary prevention implantable cardioverter defibrillator (ICD) indication who undergo ablation may be able to avoid ICD implant, according to ... Ablation of frequent premature ventricular complex allows safe withholding of ICD implant

Features


The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift
Thursday, 09 Jun 2016
We now live in an unprecedented era of technological advances, which is eclipsing our ability to test new therapies at the pace of these advances and the natural history of most heart rhythm ... The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift

Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study
Wednesday, 01 Jun 2016
Pre-clinical data, presented at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy (IDSS; 6–9 March, Tel Aviv, Israel), have shown that it is feasible ... Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study

Profiles


Etienne Aliot
Wednesday, 08 Jun 2016
Etienne Aliot (Nancy, France) has always been fascinated by the work of surgeons. This fascination ... Etienne Aliot

George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions